Next Article in Journal
Eco-Epidemiological Evidence of the Transmission of Avian and Human Influenza A Viruses in Wild Pigs in Campeche, Mexico
Next Article in Special Issue
Detection of Recombinant Rousettus Bat Coronavirus GCCDC1 in Lesser Dawn Bats (Eonycteris spelaea) in Singapore
Previous Article in Journal / Special Issue
SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Open AccessReview

Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review

Department of Medicine, Imperial College London, London W12 0NN, UK
Department of Medicine, St. George’s University of London, London SW17 0RE, UK
College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Viruses 2020, 12(5), 527;
Received: 8 April 2020 / Revised: 26 April 2020 / Accepted: 9 May 2020 / Published: 11 May 2020
(This article belongs to the Special Issue Pathogenesis of Human and Animal Coronaviruses)
In early December 2019, the coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged in Wuhan, China. As of May 10th, 2020, a total of over 4 million COVID-19 cases and 280,000 deaths have been reported globally, reflecting the raised infectivity and severity of this virus. Amongst hospitalised COVID-19 patients, there is a high prevalence of established cardiovascular disease (CVD). There is evidence showing that COVID-19 may exacerbate cardiovascular risk factors and preexisting CVD or may lead to cardiovascular complications. With intensive care units operating at maximum capacity and such staggering mortality rates reported, it is imperative during this time-sensitive COVID-19 outbreak to identify patients with an increased risk of adverse outcomes and/or myocardial injury. Preliminary findings from COVID-19 studies have shown the association of biomarkers of acute cardiac injury and coagulation with worse prognosis. While these biomarkers are recognised for CVD, there is emerging prospect that they may aid prognosis in COVID-19, especially in patients with cardiovascular comorbidities or risk factors that predispose to worse outcomes. Consequently, the aim of this review is to identify cardiovascular prognostic factors associated with morbidity and mortality in COVID-19 and to highlight considerations for incorporating laboratory testing of biomarkers of cardiovascular performance in COVID-19 to optimise outcomes. View Full-Text
Keywords: COVID-19; coronavirus; cardiovascular disease; SARS-CoV-2 COVID-19; coronavirus; cardiovascular disease; SARS-CoV-2
MDPI and ACS Style

Aboughdir, M.; Kirwin, T.; Abdul Khader, A.; Wang, B. Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review. Viruses 2020, 12, 527.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop